Alpha emitting nuclides in nuclear medicine theranostics

Abstract

Theranostic applications with radio-isotopes currently are rapidly progressing and expand nuclear medicine application in clinical routine. Alpha emitting isotopes, in particular, have long been hypothesized to achieve relevant advances for the treatment of malignancies. Here, an overview of their properties and the knowledge of radiobiology is reviewed in view of clinical translation. Clinical evidence of radiopharmaceuticals based on alpha emitters is summarized with a focus on recent developments for treatment of metastasized castration resistant prostate cancer.

Zusammenfassung

Theranostische Anwendungen mit Radioisotopen machen derzeit rasche Fortschritte und erweitern den Einsatz der Nuklearmedizin in der klinischen Routine. Insbesondere alpha-emittierenden Isotopen werden seit Langem deutliche Fortschritte bei der Behandlung bösartiger Erkrankungen zugetraut. Hier wird ein Überblick über ihre Eigenschaften und die Erkenntnisse der Radiobiologie im Hinblick auf klinische Anwendung gegeben. Die aktuellen klinischen Erfahrungen mit Radiopharmazeutika auf der Basis von Alpha-Emittern werden zusammengefasst, wobei der Schwerpunkt auf den jüngsten Entwicklungen zur Behandlung von metastasiertem kastrationsresistentem Prostatakrebs liegt.

Schlüsselwörter

hoher LET - PSMA - alpha-Strahler

Keywords

high LET - PSMA - alpha emitter

Publication History

Received: 08 September 2021

Accepted: 15 September 2021

Article published online:
08 October 2021

• References

• 1 Macklis RM, Lin JY, Beresford B, Atcher RW, Hines JJ, Humm JL. Cellular kinetics, dosimetry, and radiobiology of alpha-particle radioimmunotherapy: induction of apoptosis. Radiat Res 1992; 130 (02) 220-6 (PMID: 1574578)
• 2 Parker C, Nilsson S, Heinrich D, Helle SI, OʼSullivan JM, Fossa SD. et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013; 369 (03) 213-23 DOI: 10.1056/NEJMoa1213755. (PMID: 23863050)
• 3 Smith M, Parker C, Saad F, Miller K, Tombal B, Ng QS. et al. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2019; 20 (03) 408-19 DOI: 10.1016/S1470-2045(18)30860-X. (PMID: 30738780)
• 4 Feuerecker B, Tauber R, Knorr K, Heck M, Beheshti A, Seidl C. et al. Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA. Eur Urol 2021; 79 (03) 343-350 DOI: 10.1016/j.eururo.2020.11.013. (PMID: 33293081)
• 5 Miederer M, McDevitt MR, Borchardt P, Bergman I, Kramer K, Cheung NK. et al. Treatment of neuroblastoma meningeal carcinomatosis with intrathecal application of alpha-emitting atomic nanogenerators targeting disialo-ganglioside GD2. Clin Cancer Res 2004; 10 (20) 6985-6992 DOI: 10.1158/1078-0432.CCR-04-0859. (PMID: 15501978)
• 6 Miederer M, Thomas C, Beck J, Hampel C, Krieger C, Baque PE. et al. Haematopoietic toxicity of radium-223 in patients with high skeletal tumour burden. Nuklearmedizin 2015; 54 (05) 197-203 DOI: 10.3413/Nukmed-0751-15-06. (PMID: 26392087)
• 7 Deandreis D, Maillard A, Zerdoud S, Bournaud C, Vija L, Sajous C. et al. RADTHYR: an open-label, single-arm, prospective multicenter phase II trial of Radium-223 for the treatment of bone metastases from radioactive iodine refractory differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 2021; DOI: 10.1007/s00259-021-05229-y.
• 8 Schulte TL, Nekolla EA, Wick RR. Long-term investigation of the risk of malignant diseases following intravenous radium-224 treatment for ankylosing spondylitis. Strahlenther Onkol 2009; 185 (09) 549-556 DOI: 10.1007/s00066-009-2006-8. (PMID: 19756420)
• 9 Khreish F, Ebert N, Ries M, Maus S, Rosar F, Bohnenberger H. et al. (225)Ac-PSMA-617/(177)Lu-PSMA-617 tandem therapy of metastatic castration-resistant prostate cancer: pilot experience. Eur J Nucl Med Mol Imaging 2020; 47 (03) 721-728 DOI: 10.1007/s00259-019-04612-0. (PMID: 31758224)
• 10 Sartor AO, la Fougere C, Essler M, Ezziddin S, Kramer G, Elllinger J. et al. Lutetium-177-prostate-specific membrane antigen ligand following radium-223 treatment in men with bone-metastatic castration-resistant prostate cancer: real-world clinical experience. J Nucl Med 2021; DOI: 10.2967/jnumed.121.262240.
• 11 McDevitt MR, Ma D, Lai LT, Simon J, Borchardt P, Frank RK. et al. Tumor therapy with targeted atomic nanogenerators. Science 2001; 294: 1537-1540 DOI: 10.1126/science.1064126. (PMID: 11711678)
• 12 Mease RC, Kang C, Kumar V, Ray S, Minn IL, Brummet M. et al. An improved (211)At-labeled agent for PSMA-targeted alpha therapy. J Nucl Med 2021; DOI: 10.2967/jnumed.121.262098.
• 13 Ramdahl T, Bonge-Hansen HT, Ryan OB, Larsen S, Herstad G, Sandberg M. et al. An efficient chelator for complexation of thorium-227. Bioorg Med Chem Lett 2016; 26 (17) 4318-4321 DOI: 10.1016/j.bmcl.2016.07.034. (PMID: 27476138)
• 14 Eychenne R, Cherel M, Haddad F, Guerard F, Gestin JF. Overview of the Most Promising Radionuclides for Targeted Alpha Therapy: The "Hopeful Eight". Pharmaceutics 2021; 13 (06) DOI: 10.3390/pharmaceutics13060906. (PMID: 34207408)
• 15 Pouget JP, Constanzo J. Revisiting the Radiobiology of Targeted Alpha Therapy. Front Med (Lausanne) 2021; 8: 692436 DOI: 10.3389/fmed.2021.692436. (PMID: 34386508)
• 16 Chan HS, de Blois E, Morgenstern A, Bruchertseifer F, de Jong M, Breeman W. et al. In Vitro comparison of 213Bi- and 177Lu-radiation for peptide receptor radionuclide therapy. PLoS One 2017; 12 (07) e0181473 DOI: 10.1371/journal.pone.0181473. (PMID: 28732021)
• 17 Graf F, Fahrer J, Maus S, Morgenstern A, Bruchertseifer F, Venkatachalam S. et al. DNA double strand breaks as predictor of efficacy of the alpha-particle emitter Ac-225 and the electron emitter Lu-177 for somatostatin receptor targeted radiotherapy. PLoS One 2014; 9 (02) e88239 DOI: 10.1371/journal.pone.0088239. (PMID: 24516620)
• 18 Bannik K, Madas B, Jarzombek M, Sutter A, Siemeister G, Mumberg D. et al. Radiobiological effects of the alpha emitter Ra-223 on tumor cells. Sci Rep 2019; 9 (01) 18489 DOI: 10.1038/s41598-019-54884-7. (PMID: 31811257)
• 19 Sgouros G. Dosimetry, Radiobiology and Synthetic Lethality: Radiopharmaceutical Therapy (RPT) With Alpha-Particle-Emitters. Semin Nucl Med 2020; 50 (02) 124-132 DOI: 10.1053/j.semnuclmed.2019.11.002. (PMID: 32172797)
• 20 Basaco T, Pektor S, Bermudez JM, Meneses N, Heller M, Galvan JA. et al. Evaluation of Radiolabeled Girentuximab In Vitro and In Vivo. Pharmaceuticals (Basel) 2018; 11 (04) DOI: 10.3390/ph11040132. (PMID: 30487460)
• 21 Drecoll E, Gaertner FC, Miederer M, Blechert B, Vallon M, Muller JM. et al. Treatment of peritoneal carcinomatosis by targeted delivery of the radio-labeled tumor homing peptide bi-DTPA-[F3]2 into the nucleus of tumor cells. PLoS One 2009; 4 (05) e5715 DOI: 10.1371/journal.pone.0005715. (PMID: 19479088)
• 22 Miederer M, Henriksen G, Alke A, Mossbrugger I, Quintanilla-Martinez L, Senekowitsch-Schmidtke R. et al. Preclinical evaluation of the alpha-particle generator nuclide 225Ac for somatostatin receptor radiotherapy of neuroendocrine tumors. Clin Cancer Res 2008; 14 (11) 3555-3561 DOI: 10.1158/1078-0432.CCR-07-4647. (PMID: 18519789)
• 23 Jurcic JG. Targeted Alpha-Particle Therapy for Hematologic Malignancies. Semin Nucl Med 2020; 50 (02) 152-161 DOI: 10.1053/j.semnuclmed.2019.09.002. (PMID: 32172800)
• 24 Jurcic JG, Larson SM, Sgouros G, McDevitt MR, Finn RD, Divgi CR. et al. Targeted alpha particle immunotherapy for myeloid leukemia. Blood 2002; 100 (04) 1233-1239 (PMID: 12149203)
• 25 Hatcher-Lamarre JL, Sanders VA, Rahman M, Cutler CS, Francesconi LC. Alpha emitting nuclides for targeted therapy. Nucl Med Biol 2021; 92: 228-240 DOI: 10.1016/j.nucmedbio.2020.08.004. (PMID: 33558017)
• 26 Pfannkuchen N, Bausbacher N, Pektor S, Miederer M, Rosch F. In vivo Evaluation of [(225)Ac]Ac-DOTA(ZOL) for alpha-Therapy of Bone Metastases. Curr Radiopharm 2018; 11 (03) 223-230 DOI: 10.2174/1874471011666180604083911. (PMID: 29866026)
• 27 Beyer GJ, Miederer M, Vranjes-Duric S, Comor JJ, Kunzi G, Hartley O. et al. Targeted alpha therapy in vivo: direct evidence for single cancer cell kill using 149Tb-rituximab. Eur J Nucl Med Mol Imaging 2004; 31 (04) 547-554 DOI: 10.1007/s00259-003-1413-9. (PMID: 14722680)
• 28 Dizdarevic S, Petersen PM, Essler M, Versari A, Bourre JC, la Fougere C. et al. Interim analysis of the REASSURE (Radium-223 alpha Emitter Agent in non-intervention Safety Study in mCRPC popUlation for long-teRm Evaluation) study: patient characteristics and safety according to prior use of chemotherapy in routine clinical practice. Eur J Nucl Med Mol Imaging 2019; 46 (05) 1102-1110 DOI: 10.1007/s00259-019-4261-y. (PMID: 30637501)
• 29 Jadvar H, Colletti PM. Targeted alpha-therapy in non-prostate malignancies. Eur J Nucl Med Mol Imaging 2021; DOI: 10.1007/s00259-021-05405-0. (PMID: 33993386)
• 30 Rosenblat TL, McDevitt MR, Mulford DA, Pandit-Taskar N, Divgi CR, Panageas KS. et al. Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia. Clin Cancer Res 2010; 16 (21) 5303-5311 DOI: 10.1158/1078-0432.CCR-10-0382. (PMID: 20858843)
• 31 Linden O, Bates AT, Cunningham D, Hindorf C, Larsson E, Cleton A. et al. Thorium-227-Labeled Anti-CD22 Antibody (BAY 1862864) in Relapsed/Refractory CD22-Positive Non-Hodgkin Lymphoma: A First-in-Human, Phase I Study. Cancer Biother Radiopharm 2021; DOI: 10.1089/cbr.2020.4653. (PMID: 33887152)
• 32 Kratochwil C, Giesel FL, Bruchertseifer F, Mier W, Apostolidis C, Boll R. et al. (2)(1)(3)Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience. Eur J Nucl Med Mol Imaging 2014; 41 (11) 2106-2119 DOI: 10.1007/s00259-014-2857-9. (PMID: 25070685)
• 33 Kratochwil C, Apostolidis L, Rathke H, Apostolidis C, Bicu F, Bruchertseifer F. et al. Dosing (225)Ac-DOTATOC in patients with somatostatin-receptor-positive solid tumors: 5-year follow-up of hematological and renal toxicity. Eur J Nucl Med Mol Imaging 2021; DOI: 10.1007/s00259-021-05474-1.
• 34 Hallqvist A, Bergmark K, Back T, Andersson H, Dahm-Kahler P, Johansson M. et al. Intraperitoneal alpha-Emitting Radioimmunotherapy with (211)At in Relapsed Ovarian Cancer: Long-Term Follow-up with Individual Absorbed Dose Estimations. J Nucl Med 2019; 60 (08) 1073-1079 DOI: 10.2967/jnumed.118.220384. (PMID: 30683761)
• 35 Meredith RF, Torgue JJ, Rozgaja TA, Banaga EP, Bunch PW, Alvarez RD. et al. Safety and Outcome Measures of First-in-Human Intraperitoneal alpha Radioimmunotherapy With 212Pb-TCMC-Trastuzumab. Am J Clin Oncol 2018; 41 (07) 716-721 DOI: 10.1097/COC.0000000000000353. (PMID: 27906723)
• 36 Autenrieth ME, Seidl C, Bruchertseifer F, Horn T, Kurtz F, Feuerecker B. et al. Treatment of carcinoma in situ of the urinary bladder with an alpha-emitter immunoconjugate targeting the epidermal growth factor receptor: a pilot study. Eur J Nucl Med Mol Imaging 2018; 45 (08) 1364-1371 DOI: 10.1007/s00259-018-4003-6. (PMID: 29644393)
• 37 Krolicki L, Bruchertseifer F, Kunikowska J, Koziara H, Krolicki B, Jakucinski M. et al. Prolonged survival in secondary glioblastoma following local injection of targeted alpha therapy with (213)Bi-substance P analogue. Eur J Nucl Med Mol Imaging 2018; 45 (09) 1636-1644 DOI: 10.1007/s00259-018-4015-2. (PMID: 29713762)
• 38 Krolicki L, Bruchertseifer F, Kunikowska J, Koziara H, Pawlak D, Kulinski R. et al. Dose escalation study of targeted alpha therapy with [(225)Ac]Ac-DOTA-substance P in recurrence glioblastoma – safety and efficacy. Eur J Nucl Med Mol Imaging 2021; DOI: 10.1007/s00259-021-05350-y.
• 39 Hammer S, Hagemann UB, Zitzmann-Kolbe S, Larsen A, Ellingsen C, Geraudie S. et al. Preclinical Efficacy of a PSMA-Targeted Thorium-227 Conjugate (PSMA-TTC), a Targeted Alpha Therapy for Prostate Cancer. Clin Cancer Res 2020; 26 (08) 1985-1996 DOI: 10.1158/1078-0432.CCR-19-2268. (PMID: 31831560)
• 40 van der Doelen MJ, Mehra N, van Oort IM, Looijen-Salamon MG, Janssen MJR, Custers JAE. et al. Clinical outcomes and molecular profiling of advanced metastatic castration-resistant prostate cancer patients treated with (225)Ac-PSMA-617 targeted alpha-radiation therapy. Urol Oncol 2020; DOI: 10.1016/j.urolonc.2020.12.002.
• 41 Rathke H, Bruchertseifer F, Kratochwil C, Keller H, Giesel FL, Apostolidis C. et al. First patient exceeding 5-year complete remission after (225)Ac-PSMA-TAT. Eur J Nucl Med Mol Imaging 2021; 48 (01) 311-312 DOI: 10.1007/s00259-020-04875-y. (PMID: 32468252)
• 42 Zacherl MJ, Gildehaus FJ, Mittlmeier L, Boning G, Gosewisch A, Wenter V. et al. First Clinical Results for PSMA-Targeted alpha-Therapy Using (225)Ac-PSMA-I&T in Advanced-mCRPC Patients. J Nucl Med 2021; 62 (05) 669-674 DOI: 10.2967/jnumed.120.251017. (PMID: 33008928)
• 43 Kratochwil C, Giesel FL, Heussel CP, Kazdal D, Endris V, Nientiedt C. et al. Patients Resistant Against PSMA-Targeting alpha-Radiation Therapy Often Harbor Mutations in DNA Damage-Repair-Associated Genes. J Nucl Med 2020; 61 (05) 683-688 DOI: 10.2967/jnumed.119.234559. (PMID: 31601699)